SAN FRANCISCO, Oct. 28, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) as we speak introduced the Company will present a company replace and report monetary outcomes for the third quarter ended September 30, 2022, on Thursday, November 3, 2022.
The company replace and monetary outcomes will likely be offered through a press launch after market shut and will likely be accessible underneath Press Releases within the Investors part of the Vir web site at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology firm centered on combining immunologic insights with cutting-edge applied sciences to deal with and forestall critical infectious ailments. Vir has assembled 4 know-how platforms which can be designed to stimulate and improve the immune system by exploiting vital observations of pure immune processes. Its present improvement pipeline consists of product candidates focusing on COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts info which may be vital to traders on its web site.
